# **UNITED STATES**

# **SECURITIES**

06-1161793 (IRS Employer

Delaware (State or other jurisdiction

of incorporation)

**Identification No.)** 

3400 Central Expressway

## Edgar Filing: VISX INC - Form 8-K

### Santa Clara, CA 95051-0703

(Address of principal executive offices, including zip code)

(408) 733-2020

(Registrant s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01. Other Events

On March 2, 2005, VISX, Incorporated issued a press release announcing that its Iris Registration product had been approved by the United States Food and Drug Administration. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

### Item 9.01. Financial Statements and Exhibits

(c) Exhibits.

The following exhibit is filed herewith:

Exhibit No.	Description
99.1	Press release of the Company dated March 2, 2005

# Edgar Filing: VISX INC - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VISX, INCORPORATED

Date: March 2, 2005 By: /S/ ELIZABETH H. DÁVILA

Elizabeth H. Dávila

Chief Executive Officer

## EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release of the Company dated March 2, 2005